Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 137 entries
Sorted by: Best Match Show Resources per page
Real-time sampling of reasons for hedonic food consumption: further validation of the Palatable Eating Motives Scale.

Frontiers in psychology

Boggiano MM, Wenger LE, Turan B, Tatum MM, Sylvester MD, Morgan PR, Morse KE, Burgess EE.
PMID: 26082744
Front Psychol. 2015 Jun 01;6:744. doi: 10.3389/fpsyg.2015.00744. eCollection 2015.

Highly palatable foods play a salient role in obesity and binge-eating, and if habitually eaten to deal with intrinsic and extrinsic factors unrelated to metabolic need, may compromise adaptive coping and interpersonal skills. This study used event sampling methodology...

Cite
Boggiano MM, Wenger LE, Turan B, et al. Real-time sampling of reasons for hedonic food consumption: further validation of the Palatable Eating Motives Scale. Front Psychol. 2015;6:744doi: 10.3389/fpsyg.2015.00744.
Boggiano, M. M., Wenger, L. E., Turan, B., Tatum, M. M., Sylvester, M. D., Morgan, P. R., Morse, K. E., & Burgess, E. E. (2015). Real-time sampling of reasons for hedonic food consumption: further validation of the Palatable Eating Motives Scale. Frontiers in psychology, 6744. https://doi.org/10.3389/fpsyg.2015.00744
Boggiano, Mary M, et al. "Real-time sampling of reasons for hedonic food consumption: further validation of the Palatable Eating Motives Scale." Frontiers in psychology vol. 6 (2015): 744. doi: https://doi.org/10.3389/fpsyg.2015.00744
Boggiano MM, Wenger LE, Turan B, Tatum MM, Sylvester MD, Morgan PR, Morse KE, Burgess EE. Real-time sampling of reasons for hedonic food consumption: further validation of the Palatable Eating Motives Scale. Front Psychol. 2015 Jun 01;6:744. doi: 10.3389/fpsyg.2015.00744. eCollection 2015. PMID: 26082744; PMCID: PMC4450168.
Copy Download .nbib Format: NLM
Optimal management of subfertility in polycystic ovary syndrome.

International journal of women's health

Berger JJ, Bates GW.
PMID: 24966697
Int J Womens Health. 2014 Jun 13;6:613-21. doi: 10.2147/IJWH.S48527. eCollection 2014.

The purpose of this paper is to provide a stepwise approach to treating the infertility/subfertility associated with polycystic ovary syndrome. Defining polycystic ovary syndrome in a patient requires first investigating other possible causes for polycystic ovary morphology, acne, hirsutism,...

Cite
Berger JJ, Bates GW. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health. 2014;6:613-21doi: 10.2147/IJWH.S48527.
Berger, J. J., & Bates, G. W. (2014). Optimal management of subfertility in polycystic ovary syndrome. International journal of women's health, 6613-21. https://doi.org/10.2147/IJWH.S48527
Berger, Joshua J, and Bates, G Wright. "Optimal management of subfertility in polycystic ovary syndrome." International journal of women's health vol. 6 (2014): 613-21. doi: https://doi.org/10.2147/IJWH.S48527
Berger JJ, Bates GW. Optimal management of subfertility in polycystic ovary syndrome. Int J Womens Health. 2014 Jun 13;6:613-21. doi: 10.2147/IJWH.S48527. eCollection 2014. PMID: 24966697; PMCID: PMC4063802.
Copy Download .nbib Format: NLM
Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases.

Clinical epigenetics

Paul B, Barnes S, Demark-Wahnefried W, Morrow C, Salvador C, Skibola C, Tollefsbol TO.
PMID: 26478753
Clin Epigenetics. 2015 Oct 16;7:112. doi: 10.1186/s13148-015-0144-7. eCollection 2015.

Epigenetic modulation of gene activity occurs in response to non-genetic factors such as body weight status, physical activity, dietary factors, and environmental toxins. In addition, each of these factors is thought to affect and be affected by the gut...

Cite
Paul B, Barnes S, Demark-Wahnefried W, et al. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clin Epigenetics. 2015;7:112doi: 10.1186/s13148-015-0144-7.
Paul, B., Barnes, S., Demark-Wahnefried, W., Morrow, C., Salvador, C., Skibola, C., & Tollefsbol, T. O. (2015). Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clinical epigenetics, 7112. https://doi.org/10.1186/s13148-015-0144-7
Paul, Bidisha, et al. "Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases." Clinical epigenetics vol. 7 (2015): 112. doi: https://doi.org/10.1186/s13148-015-0144-7
Paul B, Barnes S, Demark-Wahnefried W, Morrow C, Salvador C, Skibola C, Tollefsbol TO. Influences of diet and the gut microbiome on epigenetic modulation in cancer and other diseases. Clin Epigenetics. 2015 Oct 16;7:112. doi: 10.1186/s13148-015-0144-7. eCollection 2015. PMID: 26478753; PMCID: PMC4609101.
Copy Download .nbib Format: NLM
Circadian regulation of metabolic homeostasis: causes and consequences.

Nature and science of sleep

McGinnis GR, Young ME.
PMID: 27313482
Nat Sci Sleep. 2016 May 27;8:163-80. doi: 10.2147/NSS.S78946. eCollection 2016.

Robust circadian rhythms in metabolic processes have been described in both humans and animal models, at the whole body, individual organ, and even cellular level. Classically, these time-of-day-dependent rhythms have been considered secondary to fluctuations in energy/nutrient supply/demand associated...

Cite
McGinnis GR, Young ME. Circadian regulation of metabolic homeostasis: causes and consequences. Nat Sci Sleep. 2016;8:163-80doi: 10.2147/NSS.S78946.
McGinnis, G. R., & Young, M. E. (2016). Circadian regulation of metabolic homeostasis: causes and consequences. Nature and science of sleep, 8163-80. https://doi.org/10.2147/NSS.S78946
McGinnis, Graham R, and Young, Martin E. "Circadian regulation of metabolic homeostasis: causes and consequences." Nature and science of sleep vol. 8 (2016): 163-80. doi: https://doi.org/10.2147/NSS.S78946
McGinnis GR, Young ME. Circadian regulation of metabolic homeostasis: causes and consequences. Nat Sci Sleep. 2016 May 27;8:163-80. doi: 10.2147/NSS.S78946. eCollection 2016. PMID: 27313482; PMCID: PMC4890688.
Copy Download .nbib Format: NLM
β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature.

Open heart

DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH.
PMID: 25821584
Open Heart. 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015.

β-Blockers (BBs) are an essential class of cardiovascular medications for reducing morbidity and mortality in patients with heart failure (HF). However, a large body of data indicates that BBs should not be used as first-line therapy for hypertension (HTN)....

Cite
DiNicolantonio JJ, Fares H, Niazi AK, et al. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015;2(1):e000230doi: 10.1136/openhrt-2014-000230.
DiNicolantonio, J. J., Fares, H., Niazi, A. K., Chatterjee, S., D'Ascenzo, F., Cerrato, E., Biondi-Zoccai, G., Lavie, C. J., Bell, D. S., & O'Keefe, J. H. (2015). β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open heart, 2(1), e000230. https://doi.org/10.1136/openhrt-2014-000230
DiNicolantonio, James J, et al. "β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature." Open heart vol. 2,1 (2015): e000230. doi: https://doi.org/10.1136/openhrt-2014-000230
DiNicolantonio JJ, Fares H, Niazi AK, Chatterjee S, D'Ascenzo F, Cerrato E, Biondi-Zoccai G, Lavie CJ, Bell DS, O'Keefe JH. β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart. 2015 Mar 21;2(1):e000230. doi: 10.1136/openhrt-2014-000230. eCollection 2015. PMID: 25821584; PMCID: PMC4371808.
Copy Download .nbib Format: NLM
Validation of Dual-energy X-Ray Absorptiometry to Predict Body Composition of Channel Catfish, .

Journal of the World Aquaculture Society

Johnson MS, Watts RJ, Hammer HS, Nagy TR, A Watts S.
PMID: 28348457
J World Aquac Soc. 2017 Feb;48(1):122-131. doi: 10.1111/jwas.12324. Epub 2016 Jul 04.

Dual-energy X-ray absorptiometry (DXA) provides a noninvasive way to determine lean tissue mass (LTM), fat mass (FM), bone mineral content (BMC), and bone mineral density (BMD) in humans and small mammals. Live channel catfish (n=74, 78g - 1200 g)...

Cite
Johnson MS, Watts RJ, Hammer HS, et al. Validation of Dual-energy X-Ray Absorptiometry to Predict Body Composition of Channel Catfish, . J World Aquac Soc. 2016;48(1):122-131doi: 10.1111/jwas.12324.
Johnson, M. S., Watts, R. J., Hammer, H. S., Nagy, T. R., & A Watts, S. (2017). Validation of Dual-energy X-Ray Absorptiometry to Predict Body Composition of Channel Catfish, . Journal of the World Aquaculture Society, 48(1), 122-131. https://doi.org/10.1111/jwas.12324
Johnson, Maria S, et al. "Validation of Dual-energy X-Ray Absorptiometry to Predict Body Composition of Channel Catfish, ." Journal of the World Aquaculture Society vol. 48,1 (2017): 122-131. doi: https://doi.org/10.1111/jwas.12324
Johnson MS, Watts RJ, Hammer HS, Nagy TR, A Watts S. Validation of Dual-energy X-Ray Absorptiometry to Predict Body Composition of Channel Catfish, . J World Aquac Soc. 2017 Feb;48(1):122-131. doi: 10.1111/jwas.12324. Epub 2016 Jul 04. PMID: 28348457; PMCID: PMC5365081.
Copy Download .nbib Format: NLM
Analysis of the Human Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients with Morbid Obesity.

Journal of proteomics & bioinformatics

Fang L, Kojima K, Zhou L, Crossman DK, Mobley JA, Grams J.
PMID: 26472921
J Proteomics Bioinform. 2015 Jun;8(6):133-141. doi: 10.4172/jpb.1000361. Epub 2015 Jun 08.

No longer regarded as simply a storage depot, fat is a dynamic organ acting locally and systemically to modulate energy homeostasis, glucose sensitivity, insulin resistance, and inflammatory pathways. Here, mass spectrometry was used to survey the proteome of patient...

Cite
Fang L, Kojima K, Zhou L, et al. Analysis of the Human Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients with Morbid Obesity. J Proteomics Bioinform. 2015;8(6):133-141doi: 10.4172/jpb.1000361.
Fang, L., Kojima, K., Zhou, L., Crossman, D. K., Mobley, J. A., & Grams, J. (2015). Analysis of the Human Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients with Morbid Obesity. Journal of proteomics & bioinformatics, 8(6), 133-141. https://doi.org/10.4172/jpb.1000361
Fang, Lingling, et al. "Analysis of the Human Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients with Morbid Obesity." Journal of proteomics & bioinformatics vol. 8,6 (2015): 133-141. doi: https://doi.org/10.4172/jpb.1000361
Fang L, Kojima K, Zhou L, Crossman DK, Mobley JA, Grams J. Analysis of the Human Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients with Morbid Obesity. J Proteomics Bioinform. 2015 Jun;8(6):133-141. doi: 10.4172/jpb.1000361. Epub 2015 Jun 08. PMID: 26472921; PMCID: PMC4603752.
Copy Download .nbib Format: NLM
Novel strategies for treatment of resistant hypertension.

Kidney international supplements

Judd EK, Oparil S.
PMID: 25028641
Kidney Int Suppl (2011). 2013 Dec;3(4):357-363. doi: 10.1038/kisup.2013.77.

Resistant hypertension, defined as blood pressure (BP) remaining above goal despite the use of 3 or more antihypertensive medications at maximally tolerated doses (one ideally being a diuretic) or BP that requires 4 or more agents to achieve control,...

Cite
Judd EK, Oparil S. Novel strategies for treatment of resistant hypertension. Kidney Int Suppl (2011). 2013;3(4):357-363doi: 10.1038/kisup.2013.77.
Judd, E. K., & Oparil, S. (2013). Novel strategies for treatment of resistant hypertension. Kidney international supplements, 3(4), 357-363. https://doi.org/10.1038/kisup.2013.77
Judd, Eric K, and Oparil, Suzanne. "Novel strategies for treatment of resistant hypertension." Kidney international supplements vol. 3,4 (2013): 357-363. doi: https://doi.org/10.1038/kisup.2013.77
Judd EK, Oparil S. Novel strategies for treatment of resistant hypertension. Kidney Int Suppl (2011). 2013 Dec;3(4):357-363. doi: 10.1038/kisup.2013.77. PMID: 25028641; PMCID: PMC4089769.
Copy Download .nbib Format: NLM
Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care.

Patient related outcome measures

Rhodes LA, Huisingh CE, McGwin G, Mennemeyer ST, Bregantini M, Patel N, Saaddine J, Crews JE, Girkin CA, Owsley C.
PMID: 27274329
Patient Relat Outcome Meas. 2016 May 19;7:37-48. doi: 10.2147/PROM.S98686. eCollection 2016.

PURPOSE: To assess the impact of the education program of the Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) telemedicine program on at-risk patients' knowledge about glaucoma and attitudes about eye care as well as to assess...

Cite
Rhodes LA, Huisingh CE, McGwin G, et al. Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care. Patient Relat Outcome Meas. 2016;7:37-48doi: 10.2147/PROM.S98686.
Rhodes, L. A., Huisingh, C. E., McGwin, G., Mennemeyer, S. T., Bregantini, M., Patel, N., Saaddine, J., Crews, J. E., Girkin, C. A., & Owsley, C. (2016). Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care. Patient related outcome measures, 737-48. https://doi.org/10.2147/PROM.S98686
Rhodes, Lindsay A, et al. "Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care." Patient related outcome measures vol. 7 (2016): 37-48. doi: https://doi.org/10.2147/PROM.S98686
Rhodes LA, Huisingh CE, McGwin G, Mennemeyer ST, Bregantini M, Patel N, Saaddine J, Crews JE, Girkin CA, Owsley C. Eye Care Quality and Accessibility Improvement in the Community (EQUALITY): impact of an eye health education program on patient knowledge about glaucoma and attitudes about eye care. Patient Relat Outcome Meas. 2016 May 19;7:37-48. doi: 10.2147/PROM.S98686. eCollection 2016. PMID: 27274329; PMCID: PMC4877018.
Copy Download .nbib Format: NLM
Macronutrient intake influences the effect of 25-hydroxy-vitamin d status on metabolic syndrome outcomes in african american girls.

Cholesterol

Newton AL, Hanks LJ, Ashraf AP, Williams E, Davis M, Casazza K.
PMID: 22792449
Cholesterol. 2012;2012:581432. doi: 10.1155/2012/581432. Epub 2012 Jun 26.

The objectives were to determine the effect of macronutrient modification on vitamin D status and if change in 25-hydroxy-vitamin D concentration influences components of metabolic syndrome in obese African American girls. Methods. Five-week intervention using reduced CHO (43% carbohydrate;...

Cite
Newton AL, Hanks LJ, Ashraf AP, et al. Macronutrient intake influences the effect of 25-hydroxy-vitamin d status on metabolic syndrome outcomes in african american girls. Cholesterol. 2012;2012:581432doi: 10.1155/2012/581432.
Newton, A. L., Hanks, L. J., Ashraf, A. P., Williams, E., Davis, M., & Casazza, K. (2012). Macronutrient intake influences the effect of 25-hydroxy-vitamin d status on metabolic syndrome outcomes in african american girls. Cholesterol, 2012581432. https://doi.org/10.1155/2012/581432
Newton, Anna L, et al. "Macronutrient intake influences the effect of 25-hydroxy-vitamin d status on metabolic syndrome outcomes in african american girls." Cholesterol vol. 2012 (2012): 581432. doi: https://doi.org/10.1155/2012/581432
Newton AL, Hanks LJ, Ashraf AP, Williams E, Davis M, Casazza K. Macronutrient intake influences the effect of 25-hydroxy-vitamin d status on metabolic syndrome outcomes in african american girls. Cholesterol. 2012;2012:581432. doi: 10.1155/2012/581432. Epub 2012 Jun 26. PMID: 22792449; PMCID: PMC3389646.
Copy Download .nbib Format: NLM
Diabetes-related impairment in bone strength is established early in the life course.

World journal of diabetes

Casazza K, Hanks LJ, Clines GA, Tse HM, Eberhardt AW.
PMID: 23961325
World J Diabetes. 2013 Aug 15;4(4):145-50. doi: 10.4239/wjd.v4.i4.145.

AIM: To evaluate properties of bone quantity/quality using young non-obese Type 1 (T1D)-diabetic (NOD) prone and syngenic non-diabetic (NOD.scid) mice.METHODS: Quantitative bone assessment of tibia was conducted using dual-energy X-ray absorptiometry (DXA) for the evaluation of body mass, bone...

Cite
Casazza K, Hanks LJ, Clines GA, et al. Diabetes-related impairment in bone strength is established early in the life course. World J Diabetes. 2013;4(4):145-50doi: 10.4239/wjd.v4.i4.145.
Casazza, K., Hanks, L. J., Clines, G. A., Tse, H. M., & Eberhardt, A. W. (2013). Diabetes-related impairment in bone strength is established early in the life course. World journal of diabetes, 4(4), 145-50. https://doi.org/10.4239/wjd.v4.i4.145
Casazza, Krista, et al. "Diabetes-related impairment in bone strength is established early in the life course." World journal of diabetes vol. 4,4 (2013): 145-50. doi: https://doi.org/10.4239/wjd.v4.i4.145
Casazza K, Hanks LJ, Clines GA, Tse HM, Eberhardt AW. Diabetes-related impairment in bone strength is established early in the life course. World J Diabetes. 2013 Aug 15;4(4):145-50. doi: 10.4239/wjd.v4.i4.145. PMID: 23961325; PMCID: PMC3746087.
Copy Download .nbib Format: NLM
Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study.

Current cardiovascular risk reports

Lewis CE.
PMID: 24040425
Curr Cardiovasc Risk Rep. 2011 Apr;5(2):109-112. doi: 10.1007/s12170-011-0159-3.

No abstract available.

Cite
Lewis CE. Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study. Curr Cardiovasc Risk Rep. 2011;5(2):109-112doi: 10.1007/s12170-011-0159-3.
Lewis, C. E. (2011). Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study. Current cardiovascular risk reports, 5(2), 109-112. https://doi.org/10.1007/s12170-011-0159-3
Lewis, Cora E. "Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study." Current cardiovascular risk reports vol. 5,2 (2011): 109-112. doi: https://doi.org/10.1007/s12170-011-0159-3
Lewis CE. Defining the Safety of Anacetrapib, a CETP Inhibitor, in Patients at High Risk for Coronary Heart Disease: the DEFINE study. Curr Cardiovasc Risk Rep. 2011 Apr;5(2):109-112. doi: 10.1007/s12170-011-0159-3. PMID: 24040425; PMCID: PMC3769953.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 137 entries